Share Prices & Company Research

Market News

17 Dec 2021 | 14:02

GlaxoSmithKline Covid treatment approved for use in EU

(Sharecast News) - GlaxoSmithKline and Vir Biotechnology said on Friday that the European Commission has given marketing authorisation to Xevudy - sotrovimab - for the early treatment of Covid-19. Sotrovimab is now approved in the EU for the treatment of adults and adolescents with Covid who do not require supplemental oxygen and who are at increased risk of progressing to severe disease.

The grant of the marketing authorisation in the EU is a result of the positive opinion issued on 16 December by the European Medicines Agency's Committee for Human Medicinal Products (CHMP).

Dr Hal Barron, chief scientific officer and president of R&D at GSK, said: "Since the start of the pandemic we have seen an unprecedented effort by governments, academia and industry to find solutions to help as many people as quickly as possible.

"Covid-19 therapeutics are an important part of the solution. We have already been working to lay the foundation for more patients across Europe to access sotrovimab through the Joint Procurement Agreement with the European Commission. With today's marketing authorisation we are now able to expand access, and we are discussing with governments how we can bring sotrovimab to more patients."

Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 17th May 2022
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.